213 related articles for article (PubMed ID: 16537801)
1. MYC levels govern hematopoietic tumor type and latency in transgenic mice.
Smith DP; Bath ML; Metcalf D; Harris AW; Cory S
Blood; 2006 Jul; 108(2):653-61. PubMed ID: 16537801
[TBL] [Abstract][Full Text] [Related]
2. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
3. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
Campbell KJ; Bath ML; Turner ML; Vandenberg CJ; Bouillet P; Metcalf D; Scott CL; Cory S
Blood; 2010 Oct; 116(17):3197-207. PubMed ID: 20631380
[TBL] [Abstract][Full Text] [Related]
4. Uncovering MYC's full oncogenic potential in the hematopoietic system.
Janz S
Oncogene; 2005 May; 24(22):3541-3. PubMed ID: 15782131
[TBL] [Abstract][Full Text] [Related]
5. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.
Schmidt T; Karsunky H; Gau E; Zevnik B; Elsässer HP; Möröy T
Oncogene; 1998 Nov; 17(20):2661-7. PubMed ID: 9840930
[TBL] [Abstract][Full Text] [Related]
6. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.
van Lohuizen M; Verbeek S; Krimpenfort P; Domen J; Saris C; Radaszkiewicz T; Berns A
Cell; 1989 Feb; 56(4):673-82. PubMed ID: 2537153
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
Kobzdej M; Matuszyk J; Strzadala L
Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643
[TBL] [Abstract][Full Text] [Related]
8. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
9. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.
Egle A; Harris AW; Bath ML; O'Reilly L; Cory S
Blood; 2004 Mar; 103(6):2276-83. PubMed ID: 14630790
[TBL] [Abstract][Full Text] [Related]
10. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival.
Ogilvy S; Metcalf D; Print CG; Bath ML; Harris AW; Adams JM
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14943-8. PubMed ID: 10611317
[TBL] [Abstract][Full Text] [Related]
11. Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice.
Shinto Y; Morimoto M; Katsumata M; Uchida A; Aozasa K; Okamoto M; Kurosawa T; Ochi T; Greene MI; Tsujimoto Y
Oncogene; 1995 Nov; 11(9):1729-36. PubMed ID: 7478600
[TBL] [Abstract][Full Text] [Related]
12. Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice.
Yang JT; Liu CZ; Domer P; Iannaccone P
Cancer Detect Prev; 1998; 22(5):405-15. PubMed ID: 9727621
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis.
Tuzlak S; Haschka MD; Mokina AM; Rülicke T; Cory S; Labi V; Villunger A
FEBS J; 2018 Apr; 285(8):1403-1418. PubMed ID: 29498802
[TBL] [Abstract][Full Text] [Related]
15. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc.
Haupt Y; Harris AW; Adams JM
Oncogene; 1992 May; 7(5):981-6. PubMed ID: 1570158
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
17. High frequency of myelomonocytic tumors in aging E mu L-myc transgenic mice.
Möröy T; Fisher PE; Lee G; Achacoso P; Wiener F; Alt FW
J Exp Med; 1992 Feb; 175(2):313-22. PubMed ID: 1310099
[TBL] [Abstract][Full Text] [Related]
18. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc.
Vaillant F; Blyth K; Terry A; Bell M; Cameron ER; Neil J; Stewart M
Oncogene; 1999 Nov; 18(50):7124-34. PubMed ID: 10597314
[TBL] [Abstract][Full Text] [Related]
19. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
20. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
Kelly PN; Puthalakath H; Adams JM; Strasser A
Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
